(See also Overview of Interstitial Lung Disease Overview of Interstitial Lung Disease Interstitial lung diseases are a heterogeneous group of disorders characterized by alveolar septal thickening, fibroblast proliferation, collagen deposition, and, if the process remains unchecked... read more and Langerhans Cell Histiocytosis Langerhans Cell Histiocytosis Langerhans cell histiocytosis (LCH) is a proliferation of dendritic mononuclear cells with infiltration into organs locally or diffusely. Most cases occur in children. Manifestations may include... read more .)
Pulmonary Langerhans cell histiocytosis is a disease in which monoclonal CD1a-positive Langerhans cells (a type of histiocyte) infiltrate the bronchioles and alveolar interstitium, accompanied by lymphocytes, plasma cells, neutrophils, and eosinophils. PLCH is one manifestation of Langerhans cell histiocytosis Langerhans Cell Histiocytosis Langerhans cell histiocytosis (LCH) is a proliferation of dendritic mononuclear cells with infiltration into organs locally or diffusely. Most cases occur in children. Manifestations may include... read more , which can affect many organs (most notably the lungs, skin, bones, pituitary, and lymph nodes) in isolation or simultaneously. PLCH occurs in isolation ≥ 85% of the time.
The etiology of PLCH is unknown, but the disease occurs almost exclusively in whites 20 to 40 years of age who smoke. Men and women are affected equally. Women develop disease later, but differences in age at onset by sex may represent differences in smoking behavior. Pathophysiology may involve recruitment and proliferation of Langerhans cells in response to cytokines and growth factors secreted by alveolar macrophages in response to cigarette smoke.
Typical symptoms and signs of pulmonary Langerhans cell histiocytosis are dyspnea, nonproductive cough, fatigue, fever, weight loss, and pleuritic chest pain. Ten percent to 25% of patients have sudden, spontaneous pneumothorax Pneumothorax Pneumothorax is air in the pleural space causing partial or complete lung collapse. Pneumothorax can occur spontaneously or result from trauma or medical procedures. Diagnosis is based on clinical... read more .
About 15% of patients are asymptomatic, with disease noted incidentally on a chest x-ray taken for another reason.
Bone pain due to bone cysts (18%), rash (13%), and polyuria due to central diabetes insipidus Central Diabetes Insipidus Diabetes insipidus results from a deficiency of vasopressin (antidiuretic hormone [ADH]) due to a hypothalamic-pituitary disorder (central diabetes insipidus) or from resistance of the kidneys... read more (5%) are the most common manifestations of extrapulmonary involvement and occur in up to 15% of patients, rarely being the presenting symptoms of PLCH. There are few signs of PLCH; the physical examination results are usually normal.
Pulmonary Langerhans cell histiocytosis is suspected based on history and chest x-ray and is confirmed by HRCT and bronchoscopy with biopsy and bronchoalveolar lavage.
Chest x-ray classically shows bilaterally symmetric nodular opacities in the middle and upper lung fields with cystic changes and normal or increased lung volumes. The lung bases are often spared. Appearance may mimic chronic obstructive pulmonary disease Chronic Obstructive Pulmonary Disease (COPD) Chronic obstructive pulmonary disease (COPD) is airflow limitation caused by an inflammatory response to inhaled toxins, often cigarette smoke. Alpha-1 antitrypsin deficiency and various occupational... read more (COPD) or lymphangioleiomyomatosis Lymphangioleiomyomatosis Lymphangioleiomyomatosis (LAM) is an indolent, progressive growth of smooth muscle cells throughout the lungs, pulmonary blood vessels, lymphatics, and pleurae. It is rare and occurs in young... read more .
Confirmation on HRCT of middle and upper lobe cysts (often with bizarre shapes) and/or nodules with interstitial thickening is considered diagnostic of PLCH.
Pulmonary function test Overview of Tests of Pulmonary Function Pulmonary function tests provide measures of airflow, lung volumes, gas exchange, response to bronchodilators, and respiratory muscle function. Basic pulmonary function tests available in the... read more findings are normal, restrictive, obstructive, or mixed depending on when the test is done during the course of the disease. Most commonly, the diffusing capacity for carbon monoxide (DLCO) is reduced and exercise is impaired.
Bronchoscopy and biopsy are indicated when imaging and pulmonary function tests are inconclusive. Finding > 5% of CD1a cells in bronchoalveolar lavage fluid is highly suggestive of the disease. Biopsy shows proliferation of Langerhans cells with occasional clustering of eosinophils (the origin of the outdated term eosinophilic granuloma) in the midst of cellular and fibrotic nodules that may take on a stellate configuration. Immunohistochemical staining is positive for CD1a, S-100 protein, and HLA-DR antigens.
Spontaneous resolution of symptoms occurs in some patients with minimally symptomatic pulmonary Langerhans cell histiocytosis; 5-year survival is about 75%, and median survival is 12 years. However, some patients develop slowly progressive disease, for which the clinical markers include
Persistent constitutional symptoms
Numerous cysts on chest x-ray
Low forced expiratory volume in 1 second (FEV1)/ forced vital capacity (FVC) ratio (< 66%)
High residual volume (RV)/total lung capacity (TLC) ratio (> 33%)
Need for prolonged corticosteroid use
Cause of death is respiratory insufficiency or cancer. Lung cancer Lung Carcinoma Lung carcinoma is the leading cause of cancer-related death worldwide. About 85% of cases are related to cigarette smoking. Symptoms can include cough, chest discomfort or pain, weight loss... read more risk is increased because of cigarette smoking.
The main treatment of pulmonary Langerhans cell histiocytosis is smoking cessation Smoking Cessation Most smokers want to quit and have tried doing so with limited success. Effective interventions include cessation counseling and drug treatment, such as varenicline, bupropion, or a nicotine... read more , which leads to symptom resolution in up to one third of patients.
Empiric use of corticosteroids and cytotoxic drugs is common practice even though their effectiveness is unproved.
Lung transplantation Lung and Heart-Lung Transplantation Lung or heart-lung transplantation is an option for patients who have respiratory insufficiency or failure and who remain at risk of death despite optimal medical treatment. The most common... read more is an option for otherwise healthy patients with accelerating respiratory insufficiency, but the disorder may recur in the transplanted lung if the patient continues or resumes smoking.
In pulmonary Langerhans cell histiocytosis (PLCH), monoclonal Langerhans cells proliferate in alveolar interstitium and bronchioles.
Consider PLCH in patients age 20 to 40 who smoke and in whom chest x-ray shows bilaterally symmetric nodular opacities in the middle and upper lung fields with cystic changes.
Confirm the diagnosis with high-resolution CT or, if results are inconclusive, lung biopsy.
Recommend smoking cessation.
Consider corticosteroids and cytotoxic drugs and, if smoking has ceased, lung transplantation.